vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and Omega Flex, Inc. (OFLX). Click either name above to swap in a different company.

Omega Flex, Inc. is the larger business by last-quarter revenue ($25.2M vs $19.6M, roughly 1.3× STANDARD BIOTOOLS INC.). Omega Flex, Inc. runs the higher net margin — 13.5% vs -177.4%, a 191.0% gap on every dollar of revenue. On growth, Omega Flex, Inc. posted the faster year-over-year revenue change (-6.5% vs -11.5%). Omega Flex, Inc. produced more free cash flow last quarter ($7.3M vs $-23.1M). Over the past eight quarters, Omega Flex, Inc.'s revenue compounded faster (-0.0% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Smart Omega Esports, formerly known as PLDT–Smart Omega, is a Philippine franchise-based professional esports team which competes in The Nationals, the top esports league in the Philippines sanctioned by the eSports National Association of the Philippines, and MPL Philippines. It was formed as a result of a partnership between esports team Sterling Global Dragons and corporate firms, PLDT Inc. and its mobile arm, Smart Communications.

LAB vs OFLX — Head-to-Head

Bigger by revenue
OFLX
OFLX
1.3× larger
OFLX
$25.2M
$19.6M
LAB
Growing faster (revenue YoY)
OFLX
OFLX
+5.0% gap
OFLX
-6.5%
-11.5%
LAB
Higher net margin
OFLX
OFLX
191.0% more per $
OFLX
13.5%
-177.4%
LAB
More free cash flow
OFLX
OFLX
$30.4M more FCF
OFLX
$7.3M
$-23.1M
LAB
Faster 2-yr revenue CAGR
OFLX
OFLX
Annualised
OFLX
-0.0%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
OFLX
OFLX
Revenue
$19.6M
$25.2M
Net Profit
$-34.7M
$3.4M
Gross Margin
48.5%
59.2%
Operating Margin
-168.5%
15.8%
Net Margin
-177.4%
13.5%
Revenue YoY
-11.5%
-6.5%
Net Profit YoY
-28.8%
-27.1%
EPS (diluted)
$-0.09
$0.34

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
OFLX
OFLX
Q4 25
$25.2M
Q3 25
$19.6M
$24.2M
Q2 25
$21.8M
$25.5M
Q1 25
$40.8M
$23.3M
Q4 24
$27.0M
Q3 24
$22.1M
$24.9M
Q2 24
$22.5M
$24.6M
Q1 24
$45.5M
$25.2M
Net Profit
LAB
LAB
OFLX
OFLX
Q4 25
$3.4M
Q3 25
$-34.7M
$3.7M
Q2 25
$-33.5M
$4.2M
Q1 25
$-26.0M
$3.6M
Q4 24
$4.7M
Q3 24
$-26.9M
$4.6M
Q2 24
$-45.7M
$4.5M
Q1 24
$-32.2M
$4.2M
Gross Margin
LAB
LAB
OFLX
OFLX
Q4 25
59.2%
Q3 25
48.5%
60.2%
Q2 25
48.8%
60.4%
Q1 25
48.4%
60.3%
Q4 24
61.5%
Q3 24
54.9%
61.7%
Q2 24
46.1%
61.8%
Q1 24
53.1%
59.9%
Operating Margin
LAB
LAB
OFLX
OFLX
Q4 25
15.8%
Q3 25
-168.5%
17.3%
Q2 25
-118.1%
18.5%
Q1 25
-80.8%
17.4%
Q4 24
21.4%
Q3 24
-120.9%
22.0%
Q2 24
-134.5%
21.5%
Q1 24
-132.2%
20.1%
Net Margin
LAB
LAB
OFLX
OFLX
Q4 25
13.5%
Q3 25
-177.4%
15.2%
Q2 25
-153.7%
16.3%
Q1 25
-63.8%
15.3%
Q4 24
17.4%
Q3 24
-122.0%
18.6%
Q2 24
-203.3%
18.3%
Q1 24
-70.6%
16.7%
EPS (diluted)
LAB
LAB
OFLX
OFLX
Q4 25
$0.34
Q3 25
$-0.09
$0.37
Q2 25
$-0.09
$0.41
Q1 25
$-0.07
$0.35
Q4 24
$0.45
Q3 24
$-0.07
$0.46
Q2 24
$-0.12
$0.45
Q1 24
$-0.27
$0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
OFLX
OFLX
Cash + ST InvestmentsLiquidity on hand
$129.4M
$53.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$399.7M
$84.2M
Total Assets
$539.6M
$105.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
OFLX
OFLX
Q4 25
$53.2M
Q3 25
$129.4M
$49.4M
Q2 25
$158.6M
$50.7M
Q1 25
$150.9M
$49.2M
Q4 24
$51.7M
Q3 24
$210.6M
$45.9M
Q2 24
$269.8M
$45.7M
Q1 24
$287.1M
$45.3M
Total Debt
LAB
LAB
OFLX
OFLX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
OFLX
OFLX
Q4 25
$84.2M
Q3 25
$399.7M
$84.2M
Q2 25
$424.5M
$84.0M
Q1 25
$454.6M
$83.3M
Q4 24
$83.1M
Q3 24
$489.3M
$82.0M
Q2 24
$510.3M
$80.6M
Q1 24
$577.3M
$79.6M
Total Assets
LAB
LAB
OFLX
OFLX
Q4 25
$105.0M
Q3 25
$539.6M
$103.8M
Q2 25
$557.0M
$102.8M
Q1 25
$579.6M
$102.8M
Q4 24
$105.9M
Q3 24
$681.5M
$102.9M
Q2 24
$708.7M
$99.6M
Q1 24
$777.7M
$99.2M
Debt / Equity
LAB
LAB
OFLX
OFLX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
OFLX
OFLX
Operating Cash FlowLast quarter
$-22.2M
$7.5M
Free Cash FlowOCF − Capex
$-23.1M
$7.3M
FCF MarginFCF / Revenue
-118.1%
28.9%
Capex IntensityCapex / Revenue
4.5%
0.8%
Cash ConversionOCF / Net Profit
2.20×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$15.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
OFLX
OFLX
Q4 25
$7.5M
Q3 25
$-22.2M
$2.7M
Q2 25
$-20.7M
$5.5M
Q1 25
$-30.3M
$1.6M
Q4 24
$9.8M
Q3 24
$-27.9M
$4.0M
Q2 24
$-39.0M
$4.4M
Q1 24
$-62.5M
$2.7M
Free Cash Flow
LAB
LAB
OFLX
OFLX
Q4 25
$7.3M
Q3 25
$-23.1M
$2.0M
Q2 25
$-22.6M
$5.0M
Q1 25
$-35.3M
$1.0M
Q4 24
$9.2M
Q3 24
$-30.1M
$3.6M
Q2 24
$-41.0M
$3.8M
Q1 24
$-63.3M
$2.2M
FCF Margin
LAB
LAB
OFLX
OFLX
Q4 25
28.9%
Q3 25
-118.1%
8.4%
Q2 25
-103.6%
19.6%
Q1 25
-86.6%
4.3%
Q4 24
34.1%
Q3 24
-136.4%
14.7%
Q2 24
-182.2%
15.3%
Q1 24
-138.9%
8.9%
Capex Intensity
LAB
LAB
OFLX
OFLX
Q4 25
0.8%
Q3 25
4.5%
2.5%
Q2 25
8.7%
1.7%
Q1 25
12.4%
2.4%
Q4 24
2.1%
Q3 24
10.2%
1.4%
Q2 24
8.6%
2.6%
Q1 24
1.7%
1.8%
Cash Conversion
LAB
LAB
OFLX
OFLX
Q4 25
2.20×
Q3 25
0.72×
Q2 25
1.31×
Q1 25
0.44×
Q4 24
2.08×
Q3 24
0.86×
Q2 24
0.98×
Q1 24
0.64×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

OFLX
OFLX

Segment breakdown not available.

Related Comparisons